Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Syncona Limited AGM Information 2019

Jul 30, 2019

6283_dva_2019-07-30_04af5632-10ac-4124-9e36-45c414bdabfa.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2150H

Syncona Limited

30 July 2019

Syncona Limited

Result of Annual General Meeting 

30 July 2019

At the Annual General Meeting of the Company held today, all Resolutions as set out in the 'Notice of the 2019 Annual General Meeting' dated 27 June 2019 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 13 were proposed as ordinary resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No Resolution For Against Abstain Discretion
1 Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2019, together with the Reports of the Directors and Auditors thereon 435,492,895 247,369 0 25,774
2 Re-appointment Deloitte LLP (Guernsey Branch) as Auditors 435,511,635 24,433 214,970 15,000
3 Authorise the Directors to determine the remuneration of the Auditors 435,733,447 4,076 2,742 25,774
4 Re-elect Jeremy Tigue as a Director 421,376,075 12,076,117 2,288,072 25,774
5 Elect Melanie Gee as a Director 435,735,679 0 4,586 25,774
6 Re-elect Thomas Henderson as a Director 435,554,836 183,585 1,844 25,774
7 Re-elect Rob Hutchinson as a Director 435,726,044 9,635 4,586 25,774
8 Re-elect Nigel Keen as a Director 435,304,724 430,954 4,586 25,774
9 Re-elect Nick Moss as a Director 435,734,955 724 4,586 25,774
10 Re-elect Gian Piero Reverberi as a Director 435,735,679 0 4,586 25,774
11 Re-elect Ellen Strahlman as a Director 435,735,679 0 4,586 25,774
12 Approve the directors' remuneration report. 435,688,593 49,828 1,844 25,774
13 Authority to allot shares 435,723,353 12,326 4,586 25,774
14 Authorise the Company to purchase its own shares 435,722,250 12,693 2,742 28,354
15 Disapply pre-emption rights 435,720,338 1,987 4,586 39,128

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.

The full text of the resolutions can be found in the Notice, which is available on the Company's website at www.synconaltd.com/investors.

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: +44 (0) 20 3981 7940

FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGWGUPAMUPBGUU